Insurance - Property & Casualty
Compare Stocks
5 / 10Stock Comparison
AII vs UPC vs HCI vs HCWB vs HRTG
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Insurance - Property & Casualty
Biotechnology
Insurance - Property & Casualty
AII vs UPC vs HCI vs HCWB vs HRTG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Insurance - Property & Casualty | Drug Manufacturers - Specialty & Generic | Insurance - Property & Casualty | Biotechnology | Insurance - Property & Casualty |
| Market Cap | $385M | $2M | $1.99B | $668K | $861M |
| Revenue (TTM) | $276M | $41M | $927M | $54K | $847M |
| Net Income (TTM) | $87M | $-12M | $314M | $-8M | $196M |
| Gross Margin | 52.1% | 30.3% | 66.5% | -300.7% | 47.2% |
| Operating Margin | 35.0% | -26.7% | 47.9% | -215.1% | 31.7% |
| Forward P/E | 7.0x | — | 9.2x | — | 6.1x |
| Total Debt | $4M | $9M | $68M | $7M | $100M |
| Cash & Equiv. | $173M | $34M | $1.21B | $2M | $559M |
AII vs UPC vs HCI vs HCWB vs HRTG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 25 | May 26 | Return |
|---|---|---|---|
| American Integrity … (AII) | 100 | 118.7 | +18.7% |
| Universe Pharmaceut… (UPC) | 100 | 63.8 | -36.2% |
| HCI Group, Inc. (HCI) | 100 | 90.6 | -9.4% |
| HCW Biologics Inc. (HCWB) | 100 | 4.1 | -95.9% |
| Heritage Insurance … (HRTG) | 100 | 114.5 | +14.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AII vs UPC vs HCI vs HCWB vs HRTG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AII is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 2 yrs, beta 0.49, yield 3.1%
- 3.1% yield, 2-year raise streak, vs HCI's 1.0%, (3 stocks pay no dividend)
- +22.4% vs HCWB's -95.4%
UPC lags the leaders in this set but could rank higher in a more targeted comparison.
HCI carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 20.2%, EPS growth 179.8%, 3Y rev CAGR 22.3%
- 436.8% 10Y total return vs HRTG's 119.4%
- Lower volatility, beta 0.39, Low D/E 6.1%, current ratio 1.24x
- PEG 0.19 vs HRTG's 0.39
Among these 5 stocks, HCWB doesn't own a clear edge in any measured category.
HRTG ranks third and is worth considering specifically for value.
- Better valuation composite
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.2% revenue growth vs HCWB's -97.9% | |
| Value | Better valuation composite | |
| Quality / Margins | 33.9% margin vs HCWB's -146.8% | |
| Stability / Safety | Beta 0.39 vs HCWB's 1.54, lower leverage | |
| Dividends | 3.1% yield, 2-year raise streak, vs HCI's 1.0%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +22.4% vs HCWB's -95.4% | |
| Efficiency (ROA) | 13.2% ROA vs HCWB's -30.3%, ROIC 6.8% vs -171.1% |
AII vs UPC vs HCI vs HCWB vs HRTG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
AII vs UPC vs HCI vs HCWB vs HRTG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HCI leads in 2 of 6 categories
HRTG leads 2 • AII leads 1 • UPC leads 0 • HCWB leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HCI leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCI is the larger business by revenue, generating $927M annually — 17102.4x HCWB's $54,231. HCI is the more profitable business, keeping 33.9% of every revenue dollar as net income compared to HCWB's -146.8%. On growth, HCI holds the edge at +11.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $276M | $41M | $927M | $54,231 | $847M |
| EBITDAEarnings before interest/tax | $99M | -$10M | $454M | -$11M | $281M |
| Net IncomeAfter-tax profit | $87M | -$12M | $314M | -$8M | $196M |
| Free Cash FlowCash after capex | $236M | -$15M | $431M | -$13M | $177M |
| Gross MarginGross profit ÷ Revenue | +52.1% | +30.3% | +66.5% | -3.0% | +47.2% |
| Operating MarginEBIT ÷ Revenue | +35.0% | -26.7% | +47.9% | -215.1% | +31.7% |
| Net MarginNet income ÷ Revenue | +31.6% | -30.3% | +33.9% | -146.8% | +23.1% |
| FCF MarginFCF ÷ Revenue | +85.5% | -37.2% | +46.4% | -246.9% | +20.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -14.1% | +11.9% | -93.2% | +2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -100.1% | +23.4% | -21.1% | +2.3% |
Valuation Metrics
HRTG leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 4.4x trailing earnings, HRTG trades at a 56% valuation discount to AII's 10.1x P/E. Adjusting for growth (PEG ratio), HRTG offers better value at 0.06x vs HCI's 0.13x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $385M | $2M | $2.0B | $668,096 | $861M |
| Enterprise ValueMkt cap + debt − cash | $215M | -$23M | $844M | $6M | $402M |
| Trailing P/EPrice ÷ TTM EPS | 10.14x | -0.00x | 6.15x | -0.03x | 4.44x |
| Forward P/EPrice ÷ next-FY EPS est. | 6.95x | — | 9.19x | — | 6.07x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.13x | — | 0.06x |
| EV / EBITDAEnterprise value multiple | 4.00x | — | 1.92x | — | 1.48x |
| Price / SalesMarket cap ÷ Revenue | 1.88x | 0.09x | 2.20x | 12.32x | 1.02x |
| Price / BookPrice ÷ Book value/share | 2.37x | 0.00x | 1.77x | 0.24x | 1.72x |
| Price / FCFMarket cap ÷ FCF | 2.61x | — | 4.47x | — | 4.94x |
Profitability & Efficiency
HCI leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
HRTG delivers a 47.3% return on equity — every $100 of shareholder capital generates $47 in annual profit, vs $-3 for HCWB. AII carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to HCWB's 2.46x. On the Piotroski fundamental quality scale (0–9), HCI scores 8/9 vs HCWB's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +27.6% | -27.0% | +32.0% | -2.9% | +47.3% |
| ROA (TTM)Return on assets | +6.1% | -18.6% | +13.2% | -30.3% | +8.4% |
| ROICReturn on invested capital | +107.5% | -7.8% | +6.8% | -171.1% | +15.4% |
| ROCEReturn on capital employed | +5.4% | -5.6% | +40.6% | -5.5% | +11.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 8 | 3 | 7 |
| Debt / EquityFinancial leverage | 0.02x | 0.16x | 0.06x | 2.46x | 0.20x |
| Net DebtTotal debt minus cash | -$170M | -$24M | -$1.1B | $5M | -$459M |
| Cash & Equiv.Liquid assets | $173M | $34M | $1.2B | $2M | $559M |
| Total DebtShort + long-term debt | $4M | $9M | $68M | $7M | $100M |
| Interest CoverageEBIT ÷ Interest expense | — | -22.11x | 67.24x | -8.05x | 33.88x |
Total Returns (Dividends Reinvested)
HRTG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HRTG five years ago would be worth $30,138 today (with dividends reinvested), compared to $3 for UPC. Over the past 12 months, AII leads with a +22.4% total return vs HCWB's -95.4%. The 3-year compound annual growth rate (CAGR) favors HRTG at 89.9% vs UPC's -89.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +2.5% | -27.9% | -16.7% | -71.4% | +2.7% |
| 1-Year ReturnPast 12 months | +22.4% | -41.1% | +2.4% | -95.4% | +15.3% |
| 3-Year ReturnCumulative with dividends | +22.4% | -99.9% | +209.6% | -99.4% | +585.3% |
| 5-Year ReturnCumulative with dividends | +22.4% | -100.0% | +105.3% | -99.9% | +201.4% |
| 10-Year ReturnCumulative with dividends | +22.4% | -100.0% | +436.8% | -99.9% | +119.4% |
| CAGR (3Y)Annualised 3-year return | +7.0% | -89.3% | +45.7% | -82.2% | +89.9% |
Risk & Volatility
Evenly matched — HCI and HRTG each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCI is the less volatile stock with a 0.39 beta — it tends to amplify market swings less than HCWB's 1.54 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HRTG currently trades 87.6% from its 52-week high vs HCWB's 1.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.49x | 1.26x | 0.39x | 1.54x | 0.50x |
| 52-Week HighHighest price in past year | $26.36 | $11.00 | $210.50 | $17.80 | $31.98 |
| 52-Week LowLowest price in past year | $15.77 | $2.00 | $136.37 | $0.25 | $16.83 |
| % of 52W HighCurrent price vs 52-week peak | +74.6% | +27.3% | +72.6% | +1.8% | +87.6% |
| RSI (14)Momentum oscillator 0–100 | 50.9 | 41.9 | 48.7 | 41.6 | 55.7 |
| Avg Volume (50D)Average daily shares traded | 113K | 8K | 167K | 10.8M | 282K |
Analyst Outlook
AII leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: AII as "Buy", HCI as "Buy", HRTG as "Buy". Consensus price targets imply 42.3% upside for AII (target: $28) vs -17.2% for HCI (target: $127). For income investors, AII offers the higher dividend yield at 3.12% vs HCI's 0.98%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | — | Buy |
| Price TargetConsensus 12-month target | $28.00 | — | $126.50 | — | $39.00 |
| # AnalystsCovering analysts | 5 | — | 14 | — | 9 |
| Dividend YieldAnnual dividend ÷ price | +3.1% | — | +1.0% | — | — |
| Dividend StreakConsecutive years of raises | 2 | 2 | 2 | — | 1 |
| Dividend / ShareAnnual DPS | $0.61 | — | $1.50 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.1% | 0.0% | +0.3% |
HCI leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HRTG leads in 2 (Valuation Metrics, Total Returns). 1 tied.
AII vs UPC vs HCI vs HCWB vs HRTG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is AII or UPC or HCI or HCWB or HRTG a better buy right now?
For growth investors, HCI Group, Inc.
(HCI) is the stronger pick with 20. 2% revenue growth year-over-year, versus -97. 9% for HCW Biologics Inc. (HCWB). Heritage Insurance Holdings, Inc. (HRTG) offers the better valuation at 4. 4x trailing P/E (6. 1x forward), making it the more compelling value choice. Analysts rate American Integrity Insurance Group, Inc. (AII) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — AII or UPC or HCI or HCWB or HRTG?
On trailing P/E, Heritage Insurance Holdings, Inc.
(HRTG) is the cheapest at 4. 4x versus American Integrity Insurance Group, Inc. at 10. 1x. On forward P/E, Heritage Insurance Holdings, Inc. is actually cheaper at 6. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: HCI Group, Inc. wins at 0. 19x versus Heritage Insurance Holdings, Inc. 's 0. 39x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — AII or UPC or HCI or HCWB or HRTG?
Over the past 5 years, Heritage Insurance Holdings, Inc.
(HRTG) delivered a total return of +201. 4%, compared to -100. 0% for Universe Pharmaceuticals Inc. (UPC). Over 10 years, the gap is even starker: HCI returned +436. 8% versus UPC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — AII or UPC or HCI or HCWB or HRTG?
By beta (market sensitivity over 5 years), HCI Group, Inc.
(HCI) is the lower-risk stock at 0. 39β versus HCW Biologics Inc. 's 1. 54β — meaning HCWB is approximately 294% more volatile than HCI relative to the S&P 500. On balance sheet safety, American Integrity Insurance Group, Inc. (AII) carries a lower debt/equity ratio of 2% versus 2% for HCW Biologics Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — AII or UPC or HCI or HCWB or HRTG?
By revenue growth (latest reported year), HCI Group, Inc.
(HCI) is pulling ahead at 20. 2% versus -97. 9% for HCW Biologics Inc. (HCWB). On earnings-per-share growth, the picture is similar: Heritage Insurance Holdings, Inc. grew EPS 214. 4% year-over-year, compared to -1280. 5% for HCW Biologics Inc.. Over a 3-year CAGR, HCI leads at 22. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — AII or UPC or HCI or HCWB or HRTG?
HCI Group, Inc.
(HCI) is the more profitable company, earning 33. 2% net margin versus -146. 8% for HCW Biologics Inc. — meaning it keeps 33. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCI leads at 47. 7% versus -207. 6% for HCWB. At the gross margin level — before operating expenses — HCI leads at 73. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is AII or UPC or HCI or HCWB or HRTG more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, HCI Group, Inc. (HCI) is the more undervalued stock at a PEG of 0. 19x versus Heritage Insurance Holdings, Inc. 's 0. 39x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Heritage Insurance Holdings, Inc. (HRTG) trades at 6. 1x forward P/E versus 9. 2x for HCI Group, Inc. — 3. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AII: 42. 3% to $28. 00.
08Which pays a better dividend — AII or UPC or HCI or HCWB or HRTG?
In this comparison, AII (3.
1% yield), HCI (1. 0% yield) pay a dividend. UPC, HCWB, HRTG do not pay a meaningful dividend and should not be held primarily for income.
09Is AII or UPC or HCI or HCWB or HRTG better for a retirement portfolio?
For long-horizon retirement investors, HCI Group, Inc.
(HCI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39), 1. 0% yield, +436. 8% 10Y return). HCW Biologics Inc. (HCWB) carries a higher beta of 1. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCI: +436. 8%, HCWB: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between AII and UPC and HCI and HCWB and HRTG?
These companies operate in different sectors (AII (Financial Services) and UPC (Healthcare) and HCI (Financial Services) and HCWB (Healthcare) and HRTG (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: AII is a small-cap deep-value stock; UPC is a small-cap quality compounder stock; HCI is a small-cap high-growth stock; HCWB is a small-cap quality compounder stock; HRTG is a small-cap deep-value stock. AII, HCI pay a dividend while UPC, HCWB, HRTG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.